{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Su L"],"funding":["National Natural Science Foundation of China","Natural Science Research of Jiangsu Higher Education Institutions of China","Natural Science Foundation of Jiangsu Province"],"pagination":["1761-1770"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9527591"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(10)"],"pubmed_abstract":["Renal cyst development and expansion in autosomal dominant polycystic kidney disease (ADPKD) involves over-proliferation of cyst-lining epithelial cells and excessive cystic fluid secretion. While metformin effectively inhibits renal cyst growth in mouse models of ADPKD it exhibits low potency, and thus an adenosine monophosphate-activated protein kinase (AMPK) activator with higher potency is required. Herein, we adopted a drug repurposing strategy to explore the potential of PF-06409577, an AMPK activator for diabetic nephropathy, in cellular, ex vivo and in vivo models of ADPKD. Our results demonstrated that PF-06409577 effectively down-regulated mammalian target of rapamycin pathway-mediated proliferation of cyst-lining epithelial cells and reduced cystic fibrosis transmembrane conduct"],"journal":["FEBS open bio"],"pubmed_title":["PF-06409577 inhibits renal cyst progression by concurrently inhibiting the mTOR pathway and CFTR channel activity."],"pmcid":["PMC9527591"],"funding_grant_id":["BK20200106","81803609","20KJA350001","22077110"],"pubmed_authors":["Liu H","Wang R","Zhang H","Ren Y","Fang Q","Su L","Guo D","Fu K","Yuan H","Yin L","Wang J"],"additional_accession":[]},"is_claimable":false,"name":"PF-06409577 inhibits renal cyst progression by concurrently inhibiting the mTOR pathway and CFTR channel activity.","description":"Renal cyst development and expansion in autosomal dominant polycystic kidney disease (ADPKD) involves over-proliferation of cyst-lining epithelial cells and excessive cystic fluid secretion. While metformin effectively inhibits renal cyst growth in mouse models of ADPKD it exhibits low potency, and thus an adenosine monophosphate-activated protein kinase (AMPK) activator with higher potency is required. Herein, we adopted a drug repurposing strategy to explore the potential of PF-06409577, an AMPK activator for diabetic nephropathy, in cellular, ex vivo and in vivo models of ADPKD. Our results demonstrated that PF-06409577 effectively down-regulated mammalian target of rapamycin pathway-mediated proliferation of cyst-lining epithelial cells and reduced cystic fibrosis transmembrane conduct","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-05T07:08:39.753Z","creation":"2024-11-12T02:44:24.294Z"},"accession":"S-EPMC9527591","cross_references":{"pubmed":["35748097"],"doi":["10.1002/2211-5463.13459"]}}